Polish new drugs advertising ordinance is unrealistic, says pharma industry
This article was originally published in SRA
Executive Summary
The Polish pharmaceutical industry has criticised the new health ministry's draft Ordinance on the Advertising of Medicinal Products, claiming that - if implemented - it will restrict the industry’s freedom to carry out commercial activities. The initial aim of the draft is to transpose the updated Human Medicines Directive (2001/83/EC) into the Polish legislative system, but with the restrictions it puts forward – e.g. regarding contacts between healthcare professionals and medical sales representatives –the industry regards it as unworkable.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.